ESTRO 2024 - Abstract Book

S2479

Clinical - Urology

ESTRO 2024

the corresponding 95% CI are -1.73 [-4.18, 0.72]. The estimated change in EPIC GI score at 6-month from baseline in HYPO patients and the corresponding 95% CI are -2.89 [-8.79, 3.02]. The estimated difference in change in EPIC GI scores between the treatment SBRT and HYPO and the corresponding 95% CI are 1.16 [-5.15, 7.46], indicating that we do not have sufficient evidence of difference in effects on EPIC GI functions between the two treatments.

Conclusion:

In this randomized clinical trial, statistically or clinically meaningful patient-reported outcome differences based on EPIC at an acute interval were not evident between 5 and 20 fractions of MRI-guided salvage RT. Longer-term follow up will confirm whether difference arise.

Keywords: prostate salvage radiotherapy

1977

Digital Poster

PSMA-PET and PCa: an ancillary RADIOSA study beyond a numerical definition of oligometastatic state

Chiara Lorubbio 1,2 , Giulia Marvaso 1 , Giulia Corrao 1 , Maria Giulia Vincini 1 , Mattia Zaffaroni 1 , Cristiana Fodor 1 , Francesco Mattana 3 , Lighea Airò Farulla 3,4 , Marzia Colandrea 3 , Francesco Ceci 3 , Barbara Alicja Jereczek-Fossa 1,2 1 European Institute of Oncology, Division of Radiation Oncology, Milan, Italy. 2 University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy. 3 European Institute of Oncology, Division of Nuclear Medicine, Milan, Italy. 4 University of Milan, Department of Nuclear Medicine, Milan, Italy

Purpose/Objective:

Oligometastatic disease usually relies only on the number of radiological localizations. The aim of this study is to evaluate the predictive value of volumetric parameters derived from prostate-specific membrane antigen/PET (PSMA-PET) in oligorecurrent PCa patients. The study is a spin-off analysis of the ongoing phase II randomized trial RADIOSA (NCT03940235).

Material/Methods:

Patients enrolled within the RADIOSA trial who underwent PET-PSMA at first biochemical recurrence were included.

Two experienced nuclear medicine specialists retrospectively reviewed PSMA-PET images blinded to all histopathological and clinical data. PSMA-PET quantitative parameters PSMA tumor volume (PSMA-TV) and Maximum standardized uptake values (SUVmax) were collected. Patients were stratified according to these two parameters, PSA at the first diagnosis and at the first recurrence, time between the diagnosis and the first recurrence and the site of oligometastases (bone or lymph nodal).